Connect with us

Technology

In-Licensing Opportunity: How a Pharma Leader Leveraged Scientific Innovation for Clinical and Commercial Success | DelveInsight

Published

on

A leading U.S.-based drug delivery device company known for its strong global commercial presence recognized this opportunity and aimed to expand its portfolio through in-licensing pharma innovation. With an increasing focus on patient-friendly drug administration, the company sought to in-license a dissolvable microneedle technology (dMTS)—a non-invasive platform capable of delivering a variety of drugs and vaccines through a patch format. However, the road to in-licensed products was not without hurdles.

LAS VEGAS, March 24, 2025 /PRNewswire/ — The objective was to assess dissolvable microneedle technology and identify top licensing partner companies with the right technological competencies, clinical capabilities, and commercial readiness using secondary and primary intelligence. The company needed a comprehensive pharma market assessment to evaluate potential partners developing innovative dMTS-based drug delivery systems, ensuring they had the expertise to bring novel concepts from the lab to clinical trials and, ultimately, the market.

Recognizing the situation’s complexity and the advantages of in-licensing and out-licensing, the company turned to DelveInsight, a trusted expert in pharma market intelligence and strategic licensing. Using a combination of secondary and primary intelligence, DelveInsight conducted a deep dive into the pharma in-licensing landscape, identifying the most promising players in the microneedle technology space. The assessment provided the company with a clear roadmap—pinpointing potential partners, evaluating their clinical pipelines, and determining their in-licensing agreement potential.

In the evolving pharmaceutical landscape, bridging the gap between scientific innovation and commercial success is a persistent challenge. Many blockbuster drugs and drug delivery technologies originate from smaller biotech firms or academic research centers, where groundbreaking discoveries happen, but commercial expertise is often lacking. This is where pharma in-licensing becomes a game-changer—allowing large players to acquire cutting-edge innovations and propel them toward clinical development and market success.

Looking for the right in-licensing opportunities? Reach out to us today! Get a tailored proposal and let DelveInsight guide you with expert market intelligence and strategic licensing support.

DelveInsight’s Methodology: A Strategic Approach to In-Licensing dMTS Technology

To help the company identify the right in-licensing opportunity in dissolvable microneedle technology (dMTS), DelveInsight applied a structured, intelligence-driven approach. By leveraging its expertise in pharma licensing services and conducting comprehensive assessments, DelveInsight provided actionable insights that enabled the company to make informed decisions for in-licensing pharma assets.

dMTS Market Assessment: DelveInsight conducted an in-depth pharma market assessment, analyzing the Asia-Pacific landscape for dissolvable microneedle technology and identifying growth trends, key players, and competitive positioning in the in-licensed products space.Company Assessment: DelveInsight evaluated potential licensing partners, assessing their technological capabilities, clinical progress, and commercial readiness to support a successful in-licensing agreement.Technology Assessment: A detailed review of R&D innovations, product pipelines, and formulation technology helped determine the feasibility of in-licensing drugs from top microneedle technology developers.Investment Assessment: DelveInsight analyzed funding patterns, partnerships, and acquisition trends within the dMTS sector, ensuring that potential pharma in-licensing partners had strong financial backing and a robust growth strategy.Primary Assessment: Using primary intelligence, DelveInsight conducted expert interviews, industry surveys, and KOL engagements, validating key findings and gaining deeper insights into the capabilities of potential partners.Strategic Insights on Companies: DelveInsight provided a detailed competitive analysis, highlighting the strengths, weaknesses, opportunities, and risks of various in-licensing opportunities to ensure the client partnered with the most viable company.Assessment of Own Company: By analyzing the client’s existing portfolio, commercial strengths, and expansion goals, DelveInsight identified gaps and strategic areas for growth, ensuring a strong alignment with the selected in-licensing and out-licensing in pharma opportunities.Strategic Goal Building: Finally, DelveInsight helped the company develop a clear roadmap for in-licensing success, outlining potential partnerships, deal structures, and commercialization strategies to drive clinical development and commercial milestone achievement.

Through this intelligence-backed methodology, DelveInsight provided the client with a data-driven, strategic approach to in-licensing, enabling them to secure the right licensing opportunity and expand their footprint in the drug delivery technology market.

Strategic Outcomes with DelveInsight’s Licensing Expertise:

Matrix Analysis identified and positioned the top 20 potential licensing partners based on their technological, clinical, and commercial capabilities.The client gained a clear assessment of the top companies best aligned with their strategic goals and licensing objectives (the TARGET quadrant).DelveInsight facilitated direct meetings with 4-5 high-potential companies, enabling the client to advance in-licensing discussions efficiently.

By leveraging DelveInsight’s expertise, the company successfully secured a high-value in-licensing opportunity, giving a scientific innovation the boost it needed to reach clinical development and commercial milestone achievement. This case underscores the benefits of in-licensing—a strategic approach that enables large pharmaceutical players to stay ahead of the competition by integrating cutting-edge research into their pipelines while ensuring that breakthrough therapies reach the market faster.

Exciting, isn’t it? Don’t just watch innovation happen—secure it! Explore top in-licensing opportunities with our expert guidance.

Regulatory Analysis: DelveInsight’s regulatory intelligence services simplify global approvals by consolidating complex regulatory data into a single platform. With ever-changing guidelines and country-specific requirements, navigating approvals for NCEs, biologics, biosimilars, and cell or gene therapies can be daunting. A single misstep can mean costly delays. Our experts provide clear, comparative insights into global regulatory frameworks, helping clients streamline approvals, mitigate risks, and prioritize markets with faster access.

Portfolio Management: DelveInsight’s Portfolio Management services help clients assess competencies, leverage strengths, and align strategic priorities. Our structured approach identifies market needs, optimizes resources, and enhances portfolio value. With comprehensive market intelligence, we empower organizations to make informed, data-driven decisions, minimizing risks and maximizing long-term impact for both customers and the company.

R&D Analysis: DelveInsight’s skilled research and development analyst specializes in the complexities of different indications, offering essential insights and advice to clients aiming to advance in research and development. They utilize a methodical assessment approach, aligned with industry norms, to track the progress of each drug in both pre-clinical and clinical stages. DelveInsight’s comprehensive reports are crafted to reduce uncertainties and highlight overlooked areas, providing organizations with timely and strategic intelligence.

Why Choose DelveInsight?

DelveInsight’s Licensing Services help pharma companies secure the best in-licensing and out-licensing opportunities by identifying strategic partners and facilitating successful deal-making. With expertise across all therapeutic areas and a vast global network, we provide comprehensive market intelligence, decision-mapping matrix assessments, and expert engagement services to streamline the licensing process. Our approach ensures that clients receive a curated list of potential partners, expert-led discussions, and in-depth strategic insights, making licensing decisions more effective and result-driven. In an industry where the right partnerships drive commercial success, DelveInsight’s systematic methodology ensures seamless negotiations and long-term growth.

Ready to find the perfect licensing partner? Let’s connect!

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg 

 

View original content:https://www.prnewswire.co.uk/news-releases/in-licensing-opportunity-how-a-pharma-leader-leveraged-scientific-innovation-for-clinical-and-commercial-success–delveinsight-302407772.html

Continue Reading

Technology

HUYA Inc. to Report Third Quarter 2026 Financial Results on Tuesday, November 17, 2026

Published

on

By

-Earnings Webinar Scheduled for 5:00 a.m. ET on November 17, 2026-

GUANGZHOU, China, Oct. 27, 2026 /PRNewswire/ — HUYA Inc. (“Huya” or the “Company”) (NYSE: HUYA), a leading game-related entertainment and services provider, today announced that it will report its third quarter 2026 unaudited financial results on Tuesday, November 17, 2026, before the open of U.S. markets.

The Company’s management will host a Tencent Meeting Webinar at 5:00 a.m. U.S. Eastern Time on November 17, 2026 (6:00 p.m. Beijing/Hong Kong time on November 17, 2026), to review and discuss the Company’s business and financial performance.

For participants who wish to join the webinar, please complete the online registration in advance using the links provided below. Upon registration, participants will receive an email with webinar access information, including meeting ID, meeting link, dial-in numbers, and a unique attendee ID to join the webinar.

Participant Online Registration

A live webcast of the webinar will be accessible at https://ir.huya.com, and a replay of the webcast will be available following the session.

[1] For the purpose of this announcement only, Chinese Mainland excludes the Hong Kong Special Administrative Region, the Macao Special Administrative Region of the People’s Republic of China, and Taiwan.

About HUYA Inc.

HUYA Inc. is a leading game-related entertainment and services provider. Huya delivers dynamic live streaming and video content and a rich array of services spanning games, e-sports, and other interactive entertainment genres to a large, highly engaged community of game enthusiasts. Huya has cultivated a robust entertainment ecosystem powered by AI and other advanced technologies, serving users and partners across the gaming universe, including game companies, e-sports tournament organizers, broadcasters and talent agencies. Leveraging this strong foundation, Huya has also expanded into innovative game-related services, such as game distribution, in-game item sales, advertising and more. Huya continues to extend its footprint in China and abroad, meeting the evolving needs of gamers, content creators, and industry partners worldwide.

For more information, please visit: https://ir.huya.com.

For investor and media inquiries, please contact:

In China:

HUYA Inc.
Investor Relations
Tel: +86-757-6681-1975
E-mail: ir@huya.com

Piacente Financial Communications
Jenny Cai
Tel: +86-10-6508-0677
E-mail: huya@tpg-ir.com

In the United States:

Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
E-mail: huya@tpg-ir.com

View original content:https://www.prnewswire.com/news-releases/huya-inc-to-report-third-quarter-2026-financial-results-on-tuesday-november-17-2026-302920241.html

SOURCE HUYA Inc.

Continue Reading

Technology

MEXC and Hacken Launch AI Trading Safety Handbook to Promote Safer AI Adoption

Published

on

By

MUTSAMUDU, Comoros, Oct. 27, 2026 /PRNewswire/ — MEXC, a pioneer in 0-fee digital asset trading, and blockchain security, compliance, and regulatory assurance partner Hacken, have released the MEXC × Hacken AI Trading Safety Handbook, providing practical guidance on how users and platforms can use and deploy AI-assisted and automated trading tools more safely, from research and decision support through trade execution.

The handbook follows the recent MEXC AI Trading Report, which found strong interest in AI alongside clear demand for greater control. In MEXC’s 2026 survey, willingness to use automated trading rose from 55% to 71.8% when limits on funds, positions, leverage and losses were introduced.

As AI takes a more active role in trading, the handbook emphasizes that safety cannot rely on the AI model alone. AI-facilitated actions should be checked against separate permissions, financial limits and risk controls before execution. It covers risks including credential exposure, excessive permissions, manipulated data and unintended execution, while outlining practical safeguards for both users and platforms.

For users, the handbook sets out five safety checks: Ask, Verify, Limit, Control and Review. For platforms, it outlines five principles: Guard, Limit, Approve, Controls and Test. Together, they provide a practical framework for expanding the use of AI while keeping appropriate controls in place.

“AI can make trading more accessible and efficient, but greater capability should come with stronger safeguards,” said Vugar Usi Zade, CEO of MEXC. “At MEXC, we want users to benefit from innovation, while taking a measured approach to AI adoption. Our People First principle means giving users access to new capabilities without losing sight of control, transparency and risk.”

“AI agents will soon place more orders than people do. Trust in them should be earned the way smart contracts earned it: through independent controls, continuous red-teaming and evidence anyone can verify,” said Dyma Budorin, CEO and co-founder of Hacken. “This handbook is intended to raise awareness of those risks and provide practical support for both users and platforms. As adoption grows, platforms will need to test these safeguards continuously and strengthen them as new risks emerge.”

MEXC and Hacken hope the handbook can serve as a practical reference for users and platforms as AI becomes more deeply integrated into trading, helping raise risk awareness and support safer, more responsible adoption across the industry.

About MEXC

Founded in 2018, MEXC is a leading global multi-asset trading platform built as your 0-fee gateway to infinite opportunities. Serving users across 170+ markets, MEXC provides simple and efficient access to crypto, stocks, tokenized assets, derivatives, and a growing range of TradFi-linked opportunities through one account and one gateway.

With 0 trading fees, deep liquidity, broad asset coverage, and a high-performance trading experience, MEXC is designed for retail users who want to discover earlier, act faster, and trade with fewer barriers. As crypto and traditional finance continue to converge, MEXC is committed to making global opportunities more accessible, helping users trade freely and MEXCmize every opportunity.

MEXC Official Website| X | Telegram |How to Sign Up on MEXC

About Hacken

Hacken is a security and assurance partner for financial institutions and the infrastructure they rely on: exchanges, ecosystems, custodians, banks, asset managers, and tokenization platforms. Hacken’s AI security work includes AI agent security audits and red-teaming of AI systems.

Founded in 2017, Hacken has 60+ engineers and more than 1,500 clients across industries, including the European Commission, ADGM, Ethereum Foundation, Societe Generale-Forge, MetaMask, and Bybit.

Hacken website | X | LinkedIn

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/mexc-and-hacken-launch-ai-trading-safety-handbook-to-promote-safer-ai-adoption-302920475.html

SOURCE MEXC

Continue Reading

Technology

Renoworks Appoints SaaS Sales Executive Madan Murthy as Vice President of Sales

Published

on

By

Strategic appointment strengthens enterprise sales capabilities to accelerate growth and market adoption of renoworks.ai

CALGARY, AB, Oct. 27, 2026 /PRNewswire/ — Renoworks Software Inc. (TSXV: RW) (OTC: ROWKF) (“Renoworks” or the “Company”), an industry leader in AI-powered visualization, design and lead-generation technology for the building products industry, today announced the appointment of Madan Murthy as Vice President of Sales. The appointment supports initial positive feedback from existing clients of renoworks.ai, which now requires more sales resources to move faster.

Mr. Murthy brings more than 25 years of experience building and scaling business-to-business technology and Software-as-a-Service (SaaS) organizations, with a demonstrated track record of accelerating revenue growth, acquiring enterprise customers and developing high-performing sales organizations across international markets.

The appointment comes as Renoworks enters a new phase of growth following the launch of renoworks.ai, its next-generation AI-native platform combining photorealistic visualization, product intelligence, homeowner engagement, lead generation and data analytics. The Company believes this expanded offering creates significant opportunities to deepen relationships with existing customers and attract new manufacturers, distributors, retailers and contractors seeking to leverage AI to improve customer engagement and drive sales.

“The launch of renoworks.ai represents an important step forward in our growth strategy, and we believe the opportunity to expand our market presence has never been greater,” said Doug Vickerson, Chief Executive Officer of Renoworks. “Following recent introductions of these new capabilities to the building products industry, it is evident that it is now time to strengthen our enterprise sales organization. Madan brings extensive experience scaling SaaS businesses, winning major enterprise accounts and building repeatable sales processes. His proven ability to translate innovative technology into sustainable revenue growth makes him an excellent addition to our leadership team.”

Throughout his career, Mr. Murthy has contributed to significant revenue growth across multiple technology organizations. His accomplishments include helping scale a business from $50 million to $225 million in revenue while increasing new-customer opportunity-to-close rates from 8% to 35% and improving customer retention to 98%. He has also helped grow an early-stage software company’s SaaS business to $25 million in recurring revenue, secured Fortune 500 customers and built and led a 30-person international sales organization spanning North America, Europe and Asia-Pacific.

In his new role, Mr. Murthy will focus on expanding Renoworks’ enterprise customer base, developing new market opportunities and accelerating adoption of renoworks.ai. He will work closely with the Company’s existing business development, marketing and customer success teams to strengthen its sales pipeline, enhance go-to-market execution and support long-term recurring revenue growth.

“I am excited to join Renoworks at such an important stage in its evolution,” said Madan Murthy, Vice President of Sales. “The combination of Renoworks’ established relationships across the building products industry, deep product expertise and its new AI-native platform creates a compelling opportunity for growth. I look forward to working with the team to expand our enterprise presence, develop new customer relationships and help bring the benefits of renoworks.ai to a broader market.”

About Renoworks

Renoworks Software Inc. (TSXV: RW) (OTC: ROWKF) develops and markets AI-powered software solutions for the home remodeling and new home construction industries. The Company provides manufacturers, contractors, builders and retailers with innovative digital solutions that help homeowners visualize building products on their homes, make more informed purchasing decisions and connect with industry professionals.

Through its next-generation renoworks.ai platform, the Company is expanding beyond traditional visualization to deliver advanced AI-driven design capabilities, product intelligence, lead generation, data analytics and integrated sales workflows. These solutions help industry participants enhance customer engagement, streamline the remodeling process and increase sales opportunities.

Renoworks generates revenue through its primary business lines, including Renoworks Enterprise, Renoworks PRO, Renoworks Design Services and Renoworks API.

For more information, visit www.renoworks.com and www.renoworkspro.com.

Forward Looking Information

Certain statements in this news release, other than statements of historical fact, are forward-looking information that involves various risks and uncertainties. Such statements relating to, among other things, the prospects for the Company to enhance operating results, expand adoption of its AI-powered platform and introduce new software capabilities, are necessarily subject to risks and uncertainties, some of which are significant in scope and nature. These uncertainties may cause actual results to differ from information contained herein. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and expressly qualified in their entirety by this notice.

The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/renoworks-appoints-saas-sales-executive-madan-murthy-as-vice-president-of-sales-302920217.html

SOURCE RenoWorks Software Inc.

Continue Reading

Trending